Nymox Pharmaceutical Corporation Provides Recent Updates

Nymox Pharmaceutical Corporation has announced developments regarding its Board of Directors and its prostate treatment products. Patrick Doody has retired from the board, and the company acknowledges his contributions since 2023. The dossiers for Nymox's prostate treatments have been updated, although no major approvals have been secured yet. CEO Dr. Paul Averback has actively bought shares, acquiring 50,000 recently, having previously bought 102,844 shares in October 2025.

The company mourns the passing of Co-Chairman James G. Robinson, an influential figure in Nymox's journey. Robinson was lauded for his expertise and commitment. Meanwhile, Nymox continues to advance NYMOZARFEX, a treatment for benign prostatic hyperplasia, which the company asserts to have a promising safety profile. Despite the absence of approvals, these updates reflect ongoing efforts to strengthen their market position.